Drug Used To Protect Bone May Extend Survival In Older Breast Cancer Patients
 

The AZURE trial, led by Professor Robert Coleman from the University of Sheffield, has revealed that the bisphosphonate drug zoledronic acid boosts disease-free survival in postmenopausal breast cancer patients but may have an adverse effect on younger women...

More...